FOP-FGFR1 tyrosine kinase, the product of a t(6;8) translocation, induces a fatal myeloproliferative disease in mice

Blood

Volumn 103, Issue 1, 2004, Pages 309-312

  Guasch, Géraldine ^b   Delaval, Bénédicte ^b   Arnoulet, Christine ^b   Xie, Min Jue ^b   Xerri, Luc ^b   Sainty, Danielle ^b   Birnbaum, Daniel ^b   Pébusque, Marie Josèphe ^a  

^a INSERM   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; PHOSPHOLIPASE C;

ACUTE PHASE RESPONSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CHROMOSOME TRANSLOCATION 6; CLONOGENIC ASSAY; CONTROLLED STUDY; ENZYME ACTIVITY; LYMPHOCYTE PROLIFERATION; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; STEM CELL;

EID: 0347597750     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-05-1690     Document Type: Article

References (27)

1. Chaffanet M, Popovici C, Leroux D, et al. t(6;8), t(8;9) and t(8;13) translocations associated with stem cell myeloproliferative disorders have close or identical breakpoints in chromosome region 8p11-12. Oncogene. 1998;19:945-949.
2. MacDonald D, Aguiar RC, Mason PJ, Goldman JM, Cross NC. A new proliferative disorder associated with chromosomal translocations involving 8p12: a review. Leukemia. 1995;9:1628-1630.
3. MacDonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. 2002;107:101-107.
4. Popovici C, Zhang B, Gregoire MJ, et al. The t(6; 8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor 1. Blood. 1999;93:1381-1389.
5. Guasch G, Mack GJ, Popovici C, et al. FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). Blood. 2000;95:1788-1796.
6. Guasch G, Ollendorff V, Borg JP, Birnbaum D, Pébusque MJ. 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways. Mol Cell Biol. 2001;21:8129-8142.
7. Popovici C, Adélaïde J, Ollendorff V, et al. Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13)(p12q12). Proc Natl Acad Sci U S A. 1998;98:8712-8717.
8. Xiao S, Nalabolu SR, Aster JC, et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet. 1998;18:84-87.
9. Hawley RG, Lieu FH, Fong AZ, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1994;1:136-138.
10. Markowitz D, Hesdorffer C, Ward M, Goff S, Bank A. Retroviral gene transfer using safe and efficient packaging cell lines. Ann N Y Acad Sci. 1990;612:407-414.
11. Miller A, Rosman G. Improved retroviral vectors for gene transfer and expression. Biotechniques. 1989;7:980-990.
12. Fournier E, Dubreuil P, Birnbaum D, Borg JP. Mutation at tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor. Oncogene. 1995;11:921-931.
13. Forestall SP, Dando JS, Bohnlein E, Rigg RJ. Improved detection of replication-competent retrovirus. J Virol Methods. 1996;60:171-178.
14. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature. 2000;404:193-197.
15. Hanenberg H, Xiao XL, Dilloo D, et al. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med. 1996;2:876-882.
16. Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J. 1997;16:4226-4237.
17. Ollendorff V, Guaseh G, Isnardon D, et al. Characterization of FIM-FGFR1, the fusion product of the myeloproliferative disorder-associated t(8;13) translocation. J Biol Chem. 1999;274:26922-26930.
18. Malissen M, Gillet A, Ardouin L, et al. Altered T cell development in mice with a targeted mutation of the CD3-epsilon gene. EMBO J. 1995;14:4641-4653.
19. Anderson SJ, Abraham KM, Nakayama T, Singer A, Perlmutter RM. Inhibition of T-cell receptor beta-chain gene rearrangement by overexpression of the non-receptor protein tyrosine kinase p561ck. EMBO J. 1992;11:4877-4886.
20. Spain LM, Mulligan RC. Purification and characterization of retrovirally transduced hematopoietic stem cells, Proc Natl Acad Sci U S A. 1992;89:3790-3794.
21. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-830.
22. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A. 1990;87:6649-6653.
23. Demiroglu A, Steer EJ, Heath C, et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood. 2001;98:3778-3783.
24. Fioretos T, Panagopoulos I, Lassen C, et al. Fusion of BCR to the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11; q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL. Genes Chromosomes Cancer. 2001:32:302-310.
25. Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferafive disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood. 1998;92:3829-3840.
26. Tomasson MH, Sternberg DW, Williams IR, et al. Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581. J Clin Invest. 2000;105:423-432.
27. Liu Q, Schwaller J, Kutok J, et al. Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. EMBO J. 2000;19:1827-1838.